Prime Medicine (PRME) Research & Development (2021 - 2026)

Prime Medicine (PRME) has 6 years of Research & Development data on file, last reported at $34.1 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 15.92% year-over-year to $34.1 million; the trailing twelve-month figure through Mar 2026 stood at $154.2 million (down 2.47% YoY), and the FY2025 full-year result was $160.6 million, up 3.44% from the prior year.
• Research & Development for Q1 2026 stood at $34.1 million, down from $34.7 million in the prior quarter.
• Across five years, Research & Development topped out at $44.0 million in Q3 2025 and bottomed at $13.7 million in Q1 2022.
• The 5-year median for Research & Development is $34.7 million (2025), against an average of $34.4 million.
• Peak annual rise in Research & Development reached 238.47% in 2022, while the deepest fall reached 45.05% in 2022.
• A 5-year view of Research & Development shows it stood at $29.1 million in 2022, then surged by 42.66% to $41.5 million in 2023, then declined by 17.74% to $34.1 million in 2024, then rose by 1.77% to $34.7 million in 2025, then declined by 1.74% to $34.1 million in 2026.
• The last three Research & Development figures came in at $34.1 million (Q1 2026), $34.7 million (Q4 2025), and $44.0 million (Q3 2025), per Business Quant data.

Peer Comparison